Combining Special Immune Cells with Chemotherapy for Advanced Melanoma Treatment
NCT04119024 · RecruitingThis trial studies the effects and best dose of special immune cells called IL13Ralpha2 CAR T cells. These cells are designed to help fight stage IIIC or IV melanoma and other solid tumors that have spread. The goal is to see if these modified cells can safely attack the cancer after a chemotherapy treatment.
Locations and contact
This trial is running at 3 locations in the United States. All of them are currently recruiting.
United States3 locations · 3 recruiting
- City of HopeDuarte, CaliforniaRecruiting
- Stanford Cancer InstituteStanford, CaliforniaRecruiting
- UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, CaliforniaRecruiting
Who can join
Adults aged 18 to 75 can join if they have a type of cancer that is not curable by surgery and has shown to express a specific protein. They need to be in good health overall and willing to follow the study's procedures. The trial team will confirm if each person is eligible.
What happens during the trial
Everyone in the trial will receive a chemotherapy treatment followed by the IL13Ralpha2 CAR T cells. Participants will undergo various tests, including scans and blood sample collection, throughout the study. If their disease progresses, they may receive another round of the CAR T cell infusion.
The trial team
The trial is led by Stanford University, with key investigators including Dr. Anusha Kalbasi, Dr. Allison Betof Warner, Dr. Antoni Ribas, and Dr. Yan Xing. Collaborating organizations include the Melanoma Research Alliance and the City of Hope National Medical Center.
Important dates
The trial started on October 7, 2025, and is expected to finish in October 2026. It is currently enrolling new participants.
Additional information
The trial's ID is NCT04119024. It is in Phase 1, which means it is looking at how well the treatment works and its safety. The trial is regulated by the FDA and aims to include about 18 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →